Caremark dropped Zepbound. The reversal has a date — and you have options now.
On July 1, 2025, CVS Caremark removed Zepbound (tirzepatide) from its main commercial template formulary and made Wegovy the preferred obesity GLP-1 — forcing many members to switch. On October 1, 2026, that reverses: Zepbound returns as a co-preferred option. Today the exclusion is still in effect on affected plans for roughly two more months.
If you can’t wait — or your plan keeps the exclusion — a formulary-exception request is the path now. Upload your denial. Lysco identifies the exact reason, maps the exception grounds that fit your documents, and drafts the appeal. Your first read is free.
Free to see exactly what’s wrong. $9 to unlock the full appeal — only if you choose to proceed. No subscription.
The dates that matter
The Caremark Zepbound timeline, exactly
July 1, 2025
CVS Caremark removed Zepbound from its main commercial template formulary and made Wegovy the preferred obesity GLP-1. Many members were switched off Zepbound — some mid-treatment, while stable on a working drug.
Today — July 2026
The exclusion is still in effect on plans that follow the template. If your plan does, a Zepbound claim is denied on formulary position unless you get a formulary exception approved. Roughly two months remain before the template changes.
October 1, 2026
Caremark reverses course: Zepbound returns to the main commercial template formulary as a co-preferred option alongside Wegovy. Employer plans built on the template can vary — confirm your own plan’s position and effective date before counting on it.
The scale of it: GoodRx research reported through KFF Health News found roughly 12 million people were on plans that dropped Zepbound coverage between 2025 and 2026. If this happened to you, it wasn’t personal — it was a formulary decision. One worth knowing the dates of.
What that means for you
Two paths: wait for October, or file the exception now
If you can wait and your plan follows the template, relief may arrive October 1, 2026, when Zepbound returns as co-preferred. Before you plan around that date, confirm it with your plan — Caremark’s template is the default, but employers customize their formularies, and some plans may keep the exclusion.
If you can’t wait — or your plan keeps the exclusion — a formulary-exception request is the path now. That is a documented request, supported by your prescriber, asking the plan to cover Zepbound even though it isn’t on the formulary. The grounds below fit this exact situation, and the denial of an exception request can itself be appealed.
The exception playbook
Four exception grounds that fit this exact situation
A documented obstructive sleep apnea diagnosis
In December 2024, the FDA approved Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity. Wegovy does not carry that indication. If your chart documents an OSA diagnosis that fits the label, the exception can argue the preferred drug is not appropriate for your documented indication — a recognized exception ground. Whether the indication applies to you is a decision for you and your doctor.
You were switched to Wegovy and it failed or wasn’t tolerated
If the forced switch already happened and semaglutide didn’t work for you — weight regain, loss of clinical response, or side effects you couldn’t tolerate — that documented trial and failure of the preferred drug is a classic exception ground. The record of what happened after the switch is the evidence; your prescriber’s notes carry it.
A tirzepatide-specific clinical response your prescriber can document
Zepbound (tirzepatide) and Wegovy (semaglutide) are different molecules. If your prescriber can document a clinical reason the response you had on tirzepatide matters for your treatment — results achieved, tolerability, or a documented basis for expecting the preferred alternative to be less effective or harmful for you — that reasoning belongs in the exception request.
You were stable on Zepbound when the formulary forced the switch
Being stable on your current drug is a recognized exception ground in its own right. A continuity-of-care argument — stable, documented results on Zepbound, disrupted mid-treatment by a formulary change rather than anything clinical — is exactly what this ground exists for. See the step-therapy guide for the full list of recognized exception grounds.
The clock, where it applies: under 45 CFR 156.122(c), marketplace and other essential-health-benefit plans must decide a standard formulary-exception request within 72 hours — 24 hours if expedited — and a denied exception can go to independent external review. Employer plans follow their own plan rules, so check your plan documents for the applicable deadlines. For most commercial and ACA plans, an internal appeal of a denial must be allowed within 180 days.
Build the record
What a strong Zepbound exception request attaches
The denial letter or rejection notice itself — the exact cited reason drives the whole request
Your Zepbound treatment history: start date, dose, and documented results while you were on it
If you were switched: what happened on Wegovy — dates, outcomes, side effects, and your prescriber’s notes
For the sleep-apnea path: the documented OSA diagnosis (for example, a sleep study) and a prescriber statement tying Zepbound to the FDA-labeled indication
Your plan’s own written formulary-exception policy — you can request it in writing, and the appeal quotes it back
Being honest about what’s appealable: a plan choosing which drugs to prefer on its formulary is generally legal — you usually can’t appeal the formulary decision itself. What you can contest is whether the plan correctly applied its own exception criteria to your documented facts: your diagnosis, your treatment history, and what happened when you were switched. That is where the paperwork gets decided — and where documentation wins or loses it. No one can promise an outcome.
Honest odds: in 2024 ACA Marketplace data (KFF), fewer than 1% of denied in-network claims were formally appealed — and of the appeals that were filed, about 1 in 3 ended with the denial overturned internally. Those are population numbers, not a prediction for your case; outcomes depend on your plan, denial reason, and documentation. Nobody can promise your appeal will win — anyone who does is selling something.
Questions
Caremark and Zepbound questions, answered straight
Did CVS Caremark really drop Zepbound?
Yes. Effective July 1, 2025, CVS Caremark removed Zepbound from its main commercial template formulary and made Wegovy the preferred obesity GLP-1, which forced many members to switch. Caremark then reversed course: Zepbound returns as a co-preferred option effective October 1, 2026. Note that Caremark manages many different employer plans and employers can customize their formularies — your specific plan may or may not follow the template, so confirm with your plan documents or member services.
Should I just switch to Wegovy?
That is a clinical question for you and your prescriber — Lysco never recommends a drug. Zepbound (tirzepatide) and Wegovy (semaglutide) are different molecules with different FDA labels, and people can respond differently to each. One thing worth knowing: if you already made the switch and Wegovy did not work for you or caused side effects you could not tolerate, that documented failure or intolerance is itself evidence for a formulary-exception request to get back to Zepbound.
When does Zepbound come back to the Caremark formulary?
October 1, 2026, when Zepbound returns as a co-preferred option on Caremark’s main commercial template formulary. That is the template — employer plans built on it can vary, so confirm the date and your plan’s position directly with your plan before counting on it. If your plan keeps the exclusion after that date, the formulary-exception route still applies.
How much does Lysco cost?
Your first read is free — upload the denial and see exactly what went wrong and your appeal options. If you proceed, it is a flat $9 to unlock the full ready-to-sign appeal and submission instructions. No subscription, no credit card to start.
Start your Zepbound appeal — free
Your first read is free. 30 seconds to upload. No credit card needed.
Appeal my Zepbound denialEncrypted in transit and at rest · Access controlled · Delete anytime
Lysco is an informational tool — not a law firm, medical provider, or licensed patient advocate. We don’t prescribe or recommend medications; whether any drug or indication applies to you is a decision for you and your doctor. You review, sign, and submit anything you choose to use — Lysco never contacts your insurer or pharmacy benefit manager for you. Appeal outcomes vary by plan, diagnosis, documentation, and circumstances. This page is not medical or legal advice. Zepbound and Mounjaro are trademarks of Eli Lilly and Company. Wegovy is a trademark of Novo Nordisk A/S. CVS Caremark is a trademark of CVS Health. Lysco is not affiliated with or endorsed by CVS Health.